Pretzel Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Pretzel Therapeutics's estimated annual revenue is currently $4.3M per year.
- Pretzel Therapeutics's estimated revenue per employee is $77,500
Employee Data
- Pretzel Therapeutics has 56 Employees.
- Pretzel Therapeutics grew their employee count by 4% last year.
Pretzel Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Chairman and CEO | Reveal Email/Phone |
2 | Co-Founder | Reveal Email/Phone |
3 | Chairman and CEO | Reveal Email/Phone |
4 | Co-Founder | Reveal Email/Phone |
5 | Chief Operating Officer | Reveal Email/Phone |
6 | Chief Scientific Officer | Reveal Email/Phone |
7 | SVP - Head Biology | Reveal Email/Phone |
8 | VP, Chemistry | Reveal Email/Phone |
9 | VP, DMPK | Reveal Email/Phone |
10 | VP Finance | Reveal Email/Phone |
Pretzel Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Pretzel Therapeutics?
Our mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction by leveraging a deep mechanistic understanding of mitochondrial biology. Mitochondria are essential energy-converting cellular organelles found in nearly every cell type throughout the body. Dysfunctional mitochondria are involved in more than 50 diseases. The most severe of these are broadly termed mitochondrial diseases, a group of rare genetic conditions which affect individuals of all ages. Mitochondrial dysfunction also plays an important role in more common diseases, including aging-related disorders. At Pretzel, we are developing first-in-class therapeutics that can address mitochondrial dysfunction at its roots. By taking aim at the genetic drivers of mitochondrial dysfunction, we believe our approach could be effective across a wide range of diseases which lack meaningful treatment options today.
keywords:N/AN/A
Total Funding
56
Number of Employees
$4.3M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.1M | 56 | -8% | N/A |
#2 | $7.3M | 56 | -35% | N/A |
#3 | $11.1M | 56 | N/A | N/A |
#4 | $7.3M | 56 | -20% | N/A |
#5 | $16.3M | 56 | 4% | N/A |